Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna (NASDAQ:MRNA) reported second quarter 2026 revenue of $145 million, slightly above $142 million a year earlier, with a GAAP net loss of $(782) million and GAAP EPS of $(1.97). Cost of sales fell 22% year over year, R&D declined 7%, and SG&A decreased 6%.
Cash, cash equivalents and investments totaled $6.9 billion at June 30, 2026, before a $950 million litigation payment in July. For 2026, Moderna targets up to 10% revenue growth, has lowered expected cost of sales to $1.7 billion and R&D to $2.9 billion, and now projects year-end cash and investments of $4.7–$5.2 billion.
According to Moderna, commercial progress included a COVID vaccine collaboration in Brazil, an EU joint procurement contract for up to 24 million mRESVIA doses, and multiple regulatory approvals for mRESVIA, mNEXSPIKE and combination vaccine mCOMBRIAX. A U.S. PDUFA date of August 5, 2026 is set for flu vaccine candidates mFLUSIVA and mRNA‑1010, while norovirus candidate mRNA‑1403 did not meet statistical criteria for early success at an interim Phase 3 analysis.
Moderna (NASDAQ:MRNA) announced dosing of the first U.S. participant in its Phase 1 trial of mRNA-4200, an investigational tumor-targeted cancer antigen therapy for adults with advanced or metastatic solid tumors. mRNA-4200 encodes seven antigens shared across patients and tumor types to help induce and expand T-cell responses against selected tumor targets.
The first dose was given at START Mountain Region in Salt Lake City, part of The START Center for Cancer Research network. The Phase 1 study (NCT06880549) is an open-label, multicenter, dose-escalation trial evaluating safety and tolerability of mRNA-4200 with checkpoint inhibitor therapy. mRNA-4200 is Moderna’s third off-the-shelf cancer antigen therapy and was developed with Immatics, using its XPRESIDENT® target discovery and XCUBE® bioinformatics and AI platforms.
Moderna (NASDAQ:MRNA) will hold a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results and provide a corporate update.
The live and archived webcasts will be available in the Investors section of Moderna's website.
Moderna (NASDAQ:MRNA) appointed Michael McDonnell to its Board of Directors, effective July 8, 2026. He will also serve on the Board’s Audit Committee.
McDonnell brings over 35 years of financial leadership, including CFO roles at Biogen, IQVIA, Intelsat, MCG Capital and EchoStar, plus advisory work with Goldman Sachs Asset Management and board service at Merit Medical Systems and Baxter International.
Moderna (NASDAQ:MRNA) used its June 25, 2026 Science Day to outline how its mRNA platform supports three commercial franchises and a broad early-stage pipeline.
Updates covered Horizon 2 oncology and multiple sclerosis programs, validation of a T-cell engager modality, and a new in vivo CAR-T program for autoimmune diseases.
Moderna (NASDAQ:MRNA) reported that the FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mRNA-1010, its investigational seasonal influenza vaccine, outweigh the risks in adults 50–64 and 65+. Phase 3 data and a consistent safety profile support its Biologics License Application, with a U.S. PDUFA goal date of August 5, 2026 and parallel reviews in the EU, Canada and Australia.
Moderna (Nasdaq:MRNA) will host its Investor Event - Science Day at 9:00 a.m. ET on June 25, 2026.
The event will review Moderna's research and early development programs, showing how its mRNA platform, combined with AI and robotics, is driving innovation and potential expansion into new therapeutic areas. A live webcast and a replay (for at least 30 days) will be available on the Moderna investor website.
Moderna (NASDAQ:MRNA) announced organizational changes to support three commercial franchises in infectious diseases, intismeran and rare diseases, and to prepare for potential product launches in 2027–2028.
President Dr. Stephen Hoge gains expanded operational oversight, while Ester Banque joins as Chief Commercial Officer to build global commercial capabilities and lead upcoming launches.
Moderna (NASDAQ:MRNA) and the University of Oxford received UK MHRA authorization to begin a Phase 1/2 INTERCEPT-Lynch study of mRNA-4194, an investigational mRNA cancer vaccine for people with Lynch syndrome.
The trial will assess safety, immune response and dosing, within a broader 10-year UK strategic mRNA partnership.
Moderna (Nasdaq:MRNA) will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9 at 3:20 p.m. ET.
A live webcast and a replay, available for at least 30 days, will be accessible in the Investors section of Moderna's website.